EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NYSE Amex: AIS), a leader in self-injection drug delivery technology, today announced it was awarded two Qualifying Therapeutic Discovery Project (QTDP) Grants totalling approximately $500,000. Antares applied for grants related to investments made in the Company’s ongoing development programs for Anturol(R) and VIBEX™ MTX. The QTDP provides companies engaged in pharmaceutical product development grants or tax credits for up to 50% of their qualified investments in qualifying therapeutic discovery projects for 2009 and 2010. Final grant amounts authorized reflect a reduction applied to all applicants, as the QTDP program was significantly oversubscribed.
